Previous close | 1.2800 |
Open | 1.3000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 1.2800 - 1.3000 |
52-week range | 0.9100 - 2.3200 |
Volume | |
Avg. volume | 16,027 |
Market cap | 48.414M |
Beta (5Y monthly) | 0.98 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.7000 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.00 |
MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023. Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stat
HCW Biologics Inc. ( NASDAQ:HCWB ) shareholders (or potential shareholders) will be happy to see that the Chief...
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...